Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISOPHROL vs ADVIL ALLERGY SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
Relief of symptoms of seasonal or perennial allergic rhinitis,Relief of symptoms of vasomotor rhinitis,Relief of nasal congestion associated with the common cold,Relief of sinusitis symptoms
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Dexbrompheniramine is metabolized in the liver primarily via CYP450 enzymes; pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine.
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
Approximately 50-60% bound to plasma proteins, primarily albumin.
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
Volume of distribution is approximately 1.5-2.5 L/kg, indicating extensive tissue distribution.
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Oral bioavailability is about 70-80% due to first-pass metabolism.
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
GFR 30-50 m L/min: administer every 6-8 hours. GFR 15-29 m L/min: administer every 12 hours. GFR <15 m L/min: not recommended.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: use with caution, reduce dose frequency. Child-Pugh Class C: contraindicated.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
Children 6-11 years: 1/2 tablet (3 mg dexbrompheniramine / 30 mg pseudoephedrine) orally every 4-6 hours, max 2 tablets per day. Children <6 years: not recommended.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Initiate with 1/2 tablet every 6-8 hours; monitor for anticholinergic effects and hypertension; avoid in patients >65 years due to increased risk of adverse effects.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
None.
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
Cardiovascular effects: may cause hypertension, palpitations, arrhythmias,Central nervous system stimulation: may cause insomnia, dizziness, tremor,Urinary retention: use with caution in patients with BPH or urinary obstruction,Increased intraocular pressure: avoid in narrow-angle glaucoma,Elderly patients: more sensitive to anticholinergic and cardiovascular effects
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
Severe hypertension,Coronary artery disease,Concurrent use of MAO inhibitors or within 14 days of such therapy,Narrow-angle glaucoma,Urinary retention,Severe renal impairment,Hypersensitivity to any component
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
Avoid consuming alcohol while taking Disophrol. Caffeine may increase restlessness and insomnia. There is no specific food interaction, but taking with food may reduce gastrointestinal upset.
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis with antihistamine use, but data are limited; pseudoephedrine may be associated with a small risk of gastroschisis and hemifacial microsomia. Second and third trimesters: No specific fetal risks have been clearly established; pseudoephedrine may cause fetal tachycardia and decreased uterine blood flow at high doses. Avoid in third trimester due to potential for uterine contraction inhibition and neonatal respiratory depression from antihistamines.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
DISOPHROL is excreted into breast milk. Dexchlorpheniramine: Present in low levels, M/P ratio not established; may cause irritability and drowsiness in infants. Pseudoephedrine: Excreted into breast milk with M/P ratio of approximately 2.6-3.5; may cause infant irritability and decreased milk production. Use caution and monitor infant for excessive drowsiness or irritability.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
No specific dose adjustments are recommended in pregnancy; however, use lowest effective dose and shortest duration. Due to increased plasma volume and renal clearance in pregnancy, pseudoephedrine may have reduced efficacy; dose may need empirical adjustment based on response. Avoid extended-release formulations in pregnancy.
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
Disophrol combines an antihistamine (dexbrompheniramine) and a decongestant (pseudoephedrine). Avoid in patients with hypertension, coronary artery disease, or hyperthyroidism due to pseudoephedrine's sympathomimetic effects. Monitor for anticholinergic side effects (drowsiness, dry mouth) from the antihistamine component. Use with caution in glaucoma, urinary retention, and prostatic hypertrophy.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Take this medication as prescribed; do not exceed recommended dose due to risk of serious side effects.,Avoid alcohol and other CNS depressants as they may increase drowsiness.,Do not take with other medications containing decongestants or antihistamines.,Notify your doctor if you have high blood pressure, heart disease, glaucoma, or difficulty urinating.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISOPHROL vs ADVIL ALLERGY SINUS, answered by our medical review team.
DISOPHROL is a Antihistamine/Decongestant Combination that works by Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.. ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISOPHROL and ADVIL ALLERGY SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISOPHROL is: 1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.. The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISOPHROL and ADVIL ALLERGY SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISOPHROL is classified as Category C. DISOPHROL (dexchlorpheniramine/pseudoephedrine) is classified as FDA Pregnancy Category C. First trimester: Case reports suggest a possible small increased risk of gastroschisis wi. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.